EAM
HUMA icon

Eukles Asset Management’s Humacyte HUMA Stock Holding History

Eukles Asset Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.43K Hold
4,000
– – ﹤0.01% 190
2025
Q4 		$3.84K Hold
4,000
– – ﹤0.01% 188
2025
Q3 		$6.96K Hold
4,000
– – ﹤0.01% 172
2025
Q2 		$8.36K Buy
4,000
+3,000
+300% +$5.76K ﹤0.01% 163
2025
Q1 		$1.71K Hold
1,000
– – ﹤0.01% 192
2024
Q4 		$5.05K Hold
1,000
– – ﹤0.01% 174
2024
Q3 		$5.44K Hold
1,000
– – ﹤0.01% 177
2024
Q2 		$4.8K Buy
+1,000
New +$5.21K ﹤0.01% 180

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AP
Antipodes Partners Royal Exchange, Australia $5.19B AUM 36.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Eukles Asset Management's HUMA Position: Q1 2026 in Review

Eukles Asset Management held its Humacyte (HUMA) position steady in Q1 2026 at 4,000 shares worth $2.43K. The position accounts for ﹤0.01% of the portfolio, ranked #190.

Eukles Asset Management first reported a position in HUMA in Q2 2024 and has held it in 8 quarters since. The position peaked at $8.36K in Q2 2025. 158 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

  • Eukles Asset Management held 4,000 shares of Humacyte worth $2.43K as of Q1 2026.
  • Eukles Asset Management left its Humacyte share count unchanged in Q1 2026.
  • Humacyte made up ﹤0.01% of Eukles Asset Management's portfolio in Q1 2026, its #190 holding.
  • Eukles Asset Management first reported a position in Humacyte in Q2 2024 and has held it in 8 quarters since.
  • Eukles Asset Management's Humacyte position peaked at $8.36K in Q2 2025.
  • 158 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Eukles Asset Management's 13F filing for Q1 2026, filed 5 May 2026.